TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.


Options:
A: Arm Label: 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): N/A
C: Arm Label: 100 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anamorelin HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Anamorelin HCl; Assigned to Arm(s): 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: RC-1291 HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: RC-1291 HCl | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RC-1291 HCl; Assigned to Arm(s): RC-1291 HCl | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH)
Brief Summary: The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.


Options:
A: Arm Label: Pentoxifylline; Type: EXPERIMENTAL; Interventions: Drug: Pentoxifylline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pentoxifylline; Assigned to Arm(s): Pentoxifylline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Liraglutide-placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: OTHER; Name: Liraglutide-placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3
D: Arm Label: GFT505 80mg; Type: EXPERIMENTAL; Interventions: Drug: GFT505 80mg | Arm Label: GFT505 120mg; Type: EXPERIMENTAL; Interventions: Drug: GFT505 120mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFT505 80mg; Assigned to Arm(s): GFT505 80mg | Intervention Type: DRUG; Name: GFT505 120mg; Assigned to Arm(s): GFT505 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Exercise on Multiple Risk Factors and Health Costs in Community Living Elderly Women. The Senior Fitness and Prevention Study (SEFIP)
Brief Summary: The purpose of this study is to determine whether exercise training may impact relevant risk factors and health costs of community living women older 65 years.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Music-based multitask exercises program | Arm Label: Delayed intervention control group; Type: OTHER; Interventions: Other: Music-based multitask exercises program | Intervention Type: OTHER; Name: Music-based multitask exercises program; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Music-based multitask exercises program; Assigned to Arm(s): Delayed intervention control group
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Fall prevention exercise program | Intervention Type: OTHER; Name: Fall prevention exercise program; Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: Falls Prevention Program; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: physical exercise, wellness; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Exercise on Multiple Risk Factors and Health Costs in Community Living Elderly Women. The Senior Fitness and Prevention Study (SEFIP)
Brief Summary: The purpose of this study is to determine whether exercise training may impact relevant risk factors and health costs of community living women older 65 years.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: multifactorial intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multifactorial intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2
B: Arm Label: Nintendo Wii traning; Type: EXPERIMENTAL; Interventions: Other: Nintendo wii balance training | Arm Label: EVA-soles; Type: PLACEBO_COMPARATOR; Interventions: Other: EVA-soles | Intervention Type: OTHER; Name: Nintendo wii balance training; Assigned to Arm(s): Nintendo Wii traning | Intervention Type: OTHER; Name: EVA-soles; Assigned to Arm(s): EVA-soles
C: Arm Label: Standard Care; Type: N/A; Interventions: N/A | Arm Label: Intervention group; Type: N/A; Interventions: N/A
D: Intervention Type: BEHAVIORAL; Name: physical exercise, wellness; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.


Options:
A: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
B: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
D: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.


Options:
A: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe
B: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
C: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
D: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.


Options:
A: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
B: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): B
D: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.


Options:
A: Arm Label: Secukinumab 150 mg load (Group 1); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 150 mg no load (Group 2); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 300 mg load (Group 3); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 1 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 2 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Placebo arm 1 (Group 4), Placebo arm 2 (Group 4), Secukinumab 150 mg load (Group 1), Secukinumab 150 mg no load (Group 2), Secukinumab 300 mg load (Group 3)
B: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
C: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
D: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
B: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy
C: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
D: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form
B: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
C: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.
D: Arm Label: Bimekizumab Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Adalimumab Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Adalimumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Brief Summary: The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti IL-12 monoclonal antibody/ABT-874 | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti IL-12 monoclonal antibody/ABT-874; Assigned to Arm(s): 1, 2, 3, 4, 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
B: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
C: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB
D: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D